Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells $144,565.07 in Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Andrew Callos sold 3,341 shares of the business’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $43.27, for a total transaction of $144,565.07. Following the transaction, the executive vice president now directly owns 64,434 shares in the company, valued at approximately $2,788,059.18. The trade was a 4.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Cytokinetics Stock Performance

Shares of Cytokinetics stock traded up $0.16 during trading hours on Friday, reaching $43.43. The company’s stock had a trading volume of 1,741,467 shares, compared to its average volume of 1,573,239. Cytokinetics, Incorporated has a one year low of $40.53 and a one year high of $75.71. The company’s 50 day simple moving average is $46.80 and its 200 day simple moving average is $50.92. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28. The stock has a market cap of $5.14 billion, a P/E ratio of -8.07 and a beta of 0.95.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.03. The business had revenue of $16.93 million for the quarter, compared to analyst estimates of $14.26 million. As a group, analysts expect that Cytokinetics, Incorporated will post -5.24 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on CYTK. Citigroup assumed coverage on shares of Cytokinetics in a research note on Friday, February 7th. They set a “buy” rating and a $86.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $120.00 target price on shares of Cytokinetics in a research report on Friday, February 28th. Morgan Stanley raised Cytokinetics from an “equal weight” rating to an “overweight” rating and reduced their price target for the company from $70.00 to $67.00 in a report on Thursday, February 13th. Royal Bank of Canada raised their price objective on Cytokinetics from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Wednesday, December 18th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $72.00 target price on shares of Cytokinetics in a research report on Thursday, February 6th. Two investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Cytokinetics has a consensus rating of “Moderate Buy” and an average price target of $82.00.

Institutional Trading of Cytokinetics

Hedge funds have recently made changes to their positions in the stock. Jones Financial Companies Lllp grew its stake in Cytokinetics by 189.8% during the 4th quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 374 shares during the last quarter. Centricity Wealth Management LLC acquired a new position in shares of Cytokinetics during the fourth quarter valued at $29,000. AlphaQuest LLC grew its position in shares of Cytokinetics by 113,500.0% during the fourth quarter. AlphaQuest LLC now owns 1,136 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 1,135 shares during the last quarter. J.Safra Asset Management Corp increased its holdings in shares of Cytokinetics by 62.1% in the 4th quarter. J.Safra Asset Management Corp now owns 1,751 shares of the biopharmaceutical company’s stock worth $83,000 after acquiring an additional 671 shares during the period. Finally, Blue Trust Inc. lifted its position in Cytokinetics by 85.8% in the 4th quarter. Blue Trust Inc. now owns 1,823 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 842 shares during the last quarter.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.